MicroMD emr version 7.5
|
|
- Kerry Warren
- 8 years ago
- Views:
Transcription
1 MicroMD emr version 7.5 C l i n i c a l q u a l i t y m e a s u r e c a l c u l at i o n s
2 MICROMD EMR CLINICAL QUALITY MEASURES VERSION 7.5
3 TRADEMARKS Because of the nature of the material, numerous hardware and software products are mentioned by their trade names in this publication. All product names referenced herein are trademarks of their respective companies. The MICROMD design mark is a registered trademark of Henry Schein Medical Systems, Inc., and HENRY SCHEIN and the Henry Schein logo mark are registered trademarks of HS TM, Inc. COPYRIGHT This document is covered by the terms and conditions of the license agreement and/or the non-disclosure agreement, and may not be reproduced according to the terms of that agreement, or without the written consent of Henry Schein Medical Systems, Inc. August 3, Henry Schein Medical Systems, Inc. All rights reserved. Printed in the United States. Please forward all corrections, comments or suggestions to: editor@micromd.com.
4 TABLE OF CONTENTS PREFACE Welcome to MicroMD EMR... i How This Guide is Organized... i Understanding Typographical Conventions... i Cross-References... i Text You Type Using the Keyboard... i Keys You Press and Buttons You Click... i Dialog Box, Application Window Titles, and Field Names...ii Notes, Warnings, and Tips...ii INTRODUCTION About This Guide References Core Measures and Alternate Measures Non-Supported Measures About the Clinical Quality Measures Reporting Considerations REPORTING CLINICAL QUALITY MEASURES NQF 0001 / PQRI 64 Asthma Assessment (Alternate) Code Lists for Measure NQF 0002 / PQRI 66 Appropriate Testing for Children with Pharyngitis (Alternate) Code Lists for Measure NQF Initiation (a) and Engagement (b) of Alcohol and Other Drug Dependence Treatment (Alternate) Code Lists for Measure NQF Prenatal Care Screening for HIV (Alternate) Code Lists for Measure NQF 0013 Hypertension: Blood Pressure Management (Core) Code Lists for Measure NQF 0014 Prenatal Care: Anti-D Immune Globulin (Alternate) Code Lists for Measure NQF Controlling High Blood Pressure (Alternate) Code Lists for Measure NQF Weight Assessment and Counseling for Children and Adolescents (Core) Code Lists for Measure NQF 0027 / PQRI 115 Smoking cessation advising to quit, discuss cessation medications, discuss strategies for quitting (Alternate) Code Lists for Measure NQF 0028a Preventive Care and Screening: Tobacco Use Assessment (Core) MicroMD EMR Clinical Quality Measure Calculations Version 7.5 TOC.1
5 Table of Contents Code Lists for Measure NQF 0028b Preventive Care and Screening: Tobacco Use Assessment (Core) Code Lists for Measure NQF 0031 Breast Cancer Screening (Alternate) Code Lists for Measure NQF 0032 Cervical Cancer Screening (Alternate) Code Lists for Measure NQF 0033 Chlamydia Screening for Women (Alternate) Code Lists for Measure NQF Colorectal Cancer Screening (Alternate) Code Lists for Measure NQF Use of Appropriate Medications for Asthma (Alternate) Code Lists for Measure NQF Childhood Immunization Status (Core) Code Lists for Measure NQF 0041 / PQRI 110 Influenza Immunization for patients 50 and older (Alternate) Code Lists for Measure NQF 0043 / PQRI 111 Pneumonia Vaccination for Older Adults (Alternate) Code Lists for Measure NQF 0047 / PQRI 53 Asthma Pharmacology Therapy (Alternate) Code Lists for Measure NQF Low Back Pain: Use of Imaging Studies (Alternate) Code Lists for Measure NQF 0055 / PQRI 117 Diabetes: Eye Exam (Alternate) Code Lists for Measure NQF 0056 / PQRI 163 Diabetes: Foot Exam (Alternate) Code Lists for Measure NQF 0059 / PQRI 1 Diabetes: HbA1c Poor Control (Alternate) Code Lists for Measure NQF 0061 / PQRI 3 Diabetes: Blood Pressure Management (Alternate) Code Lists for Measure NQF 0062 / PQRI 119 Diabetes: Urine Screening (Alternate) Code Lists for Measure NQF 0064 / PQRI 2 Diabetes: LDL Management and Control (Alternate) Code Lists for Measure NQF 0067 / PQRI 6 Coronary Artery Disease: Oral Antiplatelet Therapy Prescribed (Alternate) Code Lists for Measure NQF 0068 / PQRI 204 Ischemic Vascular Disease: Use of Aspirin or another Antithrombotic (Alternate) Code Lists for Measure NQF 0070 / PQRI 7 Coronary Artery Disease: Beta Blocker Therapy for CAD Patients with Prior MI (Alternate) Code Lists for Measure NQF 0073 / PQRI 201 Ischemic Vascular Disease: Blood Pressure Management (Alternate) Code Lists for Measure TOC.2 MicroMD EMR Clinical Quality Measure Calculations Version 7.5
6 Table of Contents NQF 0074 / PQRI 197 Coronary Artery Disease: Drug Therapy for Lowering LDL Cholesterol (Alternate) Code Lists for Measure NQF 0075 Ischemic Vascular Disease: Complete Lipid Panel and LDL Control (Alternate) Code Lists for Measure NQF 0081 / PQRI 5 Heart Failure: ACE Inhibitor or ARB Therapy for LVSD (Alternate) Code Lists for Measure NQF 0083 / PQRI 8 Heart Failure: Beta Blocker Therapy for LVSD (Alternate) Code Lists for Measure NQF 0084 / PQRI 200 Heart Failure: Warfarin Therapy for Patients with Atrial Fib (Alternate) Code Lists for Measure NQF 0086 / PQRI 12 Primary Open Angle Glaucoma: Optic Nerve Evaluation (Not Supported) NQF 0088 / PQRI 18 Diabetic Retinopathy Documentation of Presence of Macular Edema and Level of Severity Retinopathy (Not Supported) NQF 0089 / PQRI 19 Diabetic Retinopathy Communicating with the physician managing ongoing Diabetes care. (Not Supported) NQF 0105 / PQRI 9 Anti-Depressant medication management: A: Effective acute phase treatment B: effective continuation (Alternate) Code Lists for Measure NQF 0385 / PQRI 72 Oncology Colon Cancer: Chemo for State III Colon Cancer Patients (Non-Supported) NQF 0387 / PQRI 71 Oncology Breast Cancer: Hormonal Therapy for State IC-IIIC ER/PR Positive Breast Cancer (Not Supported) NQF 0389 / PQRI 102 Prostate Cancer: Avoidance of Overuse of Bone Scan for staging low risk cancer patients (Alternate) Code Lists for Measure NQF 0421 / PQRI 128 Adult Weight Screening and Follow-Up (Core) Code Lists for Measure NQF 0575 Diabetes: HgA1c Control <8.0% (Alternate) Code Lists for Measure MicroMD EMR Clinical Quality Measure Calculations Version 7.5 TOC.3
7 Table of Contents TOC.4 MicroMD EMR Clinical Quality Measure Calculations Version 7.5
8 PREFACE WELCOME TO MICROMD EMR From all of us here at Henry Schein Medical Systems, Inc., thank you for selecting MicroMD EMR, the definitive Electronic Medical Records (EMR) solution. This manual is a reference to the Clinical Quality Measures supported and calculated by MicroMD EMR. This manual does not cover hardware setup, networking, or installation of the program. HOW THIS GUIDE IS ORGANIZED We have organized this guide according to the modules within MicroMD EMR. The discussion consists mainly of the new features within the modules. You can find in-depth information about the entire module in the MicroMD EMR User s Reference Manual located in the Help menu of MicroMD EMR. UNDERSTANDING TYPOGRAPHICAL CONVENTIONS Before using this manual, it is important to understand the typographical conventions used to identify and describe information. Cross-References Cross-references to chapters, sections, page numbers, headings, etc. are shown in an italic typeface. e.g., Refer to Understanding Typographical Conventions on page i. Text You Type Using the Keyboard Text that you type using the keyboard is shown in a Courier typeface. e.g., Type Anthony Smith in the Name field. Keys You Press and Buttons You Click Keys that you press on the keyboard and buttons/icons that you click with the mouse are shown in a bold sans-serif typeface. e.g., Press Enter. e.g., Click OK to continue. MicroMD EMR Clinical Quality Measure Calculations Version 7.5 i
9 Preface Dialog Box, Application Window Titles, and Field Names The titles of dialog boxes and application windows are shown in italics. Field names and selections made from dropdown menus, etc. are also shown in italics. e.g., The Print Preview dialog box appears. e.g., Select Commercial Insurance from the drop-down list. Notes, Warnings, and Tips Notes, tips and warnings are provided throughout the manual. These provide additional information that is important for you to know about the topic. NOTE A note is an important piece of information. STOP You should definitely read the information in a warning. It could help you prevent a disaster. TIP A tip table helps you with some interesting information about different ways to use the program. ii MicroMD EMR Clinical Quality Measure Calculations Version 7.5
10 INTRODUCTION CHAPTER 1 ABOUT THIS GUIDE This guide documents the Clinical Quality Measures (CQM) that are supported and calculated by MicroMD EMR version 7.5. MicroMD EMR version 7.5 was designed to comply with the requirements of the CMS EHR Incentive Program and Stage 1 Meaningful Use requirements for eligible providers. REFERENCES Additional information about HITECH Measures can be found at the sites below: The CMS EHR Incentive Program offers eligible providers opportunities for incentive payments over a multiple year period. For details on the program, visit MicroMD EMR version 7.5 has been certified under the ONC EHR Certification program as a Complete EHR Solution. Requirements for testing of HITECH Measures under the certification included testing for all core measures and menu-set measures. All additional measures are available to MicroMD EMR users for calculation and use in qualifying for the incentives offered in the CMS EHR Incentive Program. To reference the certification listing for MicroMD EMR version 7.5, please visit CORE MEASURES AND ALTERNATE MEASURES The CMS EHR Incentive Program requires each eligible provider to report three core measures and three alternate measures to demonstrate Stage 1 of Meaningful Use. There are three Required Core CQMs and three Alternate Core CQMs. Eligible providers must report on the three Required Core CQMs. If a physician reports 0 (zero) for one or more of the three Required Core CQMs, he or she must then report on up to three Alternate Core CQMs. (Some specialists, therefore, may have to report on as many as three alternate CQMs.) The three core measures are required for all providers to submit and include: NQF 0013 NQF 0028a NQF 0028b NQF 0421 Hypertension: Blood Pressure Management Preventive Care and Screening: Tobacco Use Assessment (Core) Preventive Care and Screening: Tobacco Use Assessment Adult Weight Screening and Follow-Up The three alternate core measures to submit include: NQF 0024 NQF 0038 NQF 0041 Weight Assessment and Counseling for Children and Adolescents Childhood Immunization Status Influenza Vaccine for Patients 50 years and Older The alternate measures are designed to allow providers to select measures that pertain to the specialty or patient population that they serve. Three must be reported, but providers may track as many measures as they like. MicroMD EMR Clinical Quality Measure Calculations Version
11 Chapter 1. INTRODUCTION NON-SUPPORTED MEASURES MicroMD EMR version 7.5 supports and calculates all but five of the listed Clinical Quality Measures. The five listed measures that are not supported are measurements designed to be used by ophthalmologists and oncologists. As the MicroMD EMR software is not designed for use in these specialties, these measures are not supported: NQF 0086 / PQRI 12 Primary Open Angle Glaucoma: Optic Nerve Evaluation NQF 0088 / PQRI 18 Diabetic Retinopathy Documentation of Presence of Macular Edema and Level of Severity Retinopathy NQF 0089 / PQRI 19 Diabetic Retinopathy Communicating with the physician managing ongoing Diabetes care. (Not Supported) NQF 0385 / PQRI 72 Oncology Colon Cancer: Chemo for State III Colon Cancer Patients NQF 0387 / PQRI 71 Oncology Breast Cancer: Hormonal Therapy for State IC-IIIC ER/PR Positive Breast Cancer ABOUT THE CLINICAL QUALITY MEASURES Each Clinical Quality Measure is designed to calculate the compliance with standards in delivery of healthcare. Henry Schein Medical Systems has followed the measurement documentation (as published by the NQF) in the design of the Clinical Quality Measures reporting module. Each documented measure contains the following elements: NQF Measure Number the number assigned by the National Quality Forum for this quality measurement. PQRI Measure Number the number assigned by CMS for use in the Physician Quality Reporting Initiative (PQRS - Physician Quality Reporting System). Description provides a brief description of the CQM and what it is intending to measure. Note that the descriptions are brief and may not always indicate the detailed nature of the measure. It is important to review the measure in its entirety to understand the calculation completely. Clinical Rationale provides the rationale and purpose of the measurement. Measure Calculation requires a denominator, numerator and exclusions from the calculation. Denominator describes the patients that should be included in the measurement calculation. In other words, these patients qualify to be included in the calculation. For example, if the measurement is looking for diabetic patients who have had an eye exam, the Denominator would include all diabetic patients. Numerator describes the patients in the Denominator who have satisfied the requirements of the measure. For example, if the measurement is looking for diabetic patients who had an eye exam, the numerator would only be the patients who had the eye exam. Exclusions describes patients who should not be included in the measurement (either Denominator or Numerator) because of a clinical indication in their chart. Typically these measurements are considered clinically inappropriate for patients due to their prior history or current health status. For example, a patient with his or her appendix removed would not be included in a measure testing the treatment of appendicitis. Code Lists are used extensively throughout the Clinical Quality Measures documentation. The code lists contain the approved codes that should be used to document a condition or action in the patient s chart. Note that these codes are provided by NQF in the documentation of each measure. Code lists that are referenced are: 1.2 MicroMD EMR Clinical Quality Measure Calculations Version 7.5
12 Reporting Considerations Chapter 1. INTRODUCTION ICD-9 and ICD-10 - represent the documentation of a patient s diagnosis. CPT, HCSPS - represents services provided to the patient. LOINC - (Logical Observation Identifiers Names and Codes) represents the standard nomenclature for lab results. CVX - represents the standard nomenclature for immunization. Practices reporting the measurements that involve immunizations will need to update their immunization listing to include the CVX codes. This may involve referring to documentation provided with the immunizations or referring to the following lists provided online by Centers for Disease Control (CDC): Provides a list by vaccine type: Provides a list by tradename for the vaccine: REPORTING CONSIDERATIONS NOTE MicroMD EMR does not support the use of user-defined codes and medications in the calculation of the Clinical Quality Measures. Reporting Period - Users of MicroMD EMR version 7.5 can choose to calculate the Clinical Quality Measure reporting at any time and may specify a reporting period. This reporting period typically follows a reporting year but may be modified to include any date range. Lookback Periods These periods represent the time prior to the encounter or the end of the reporting period that are considered for the measure calculation. It is important to consider that the lookback period may be prior to the reporting period and any practice may not have collected the data required to satisfy the measure based on the lookback period requirements. While this data disparity will correct itself over time by collecting the data for the measurement in the future, the initial results may not reflect the actual compliance with the measurement. Qualifying Encounters Please note that the basis for CQM reporting is the patient encounter. Patients will only be considered in the calculations when an encounter has been created during the specified reporting period. Patient Age Calculation For most measures, the patient s age is calculated at the beginning of the reporting period. Lab Results These must be documented with numeric values only and must not use special characters (!, %, etc). Additionally, most lab results look to a LOINC code associated with the result. Note that LOINC is a recognized standard for each lab result. Settings in MicroMD EMR Manager allow you to link your existing lab results to a LOINC result. Similar Measurements Several measures are focused on certain groups of patients or types of care. The similarities in these measures may lead practices to implement the quality measures simultaneously for these patient groups: MicroMD EMR Clinical Quality Measure Calculations Version
13 Chapter 1. INTRODUCTION Asthma 0001, 0036, 0047 Cancer Screening 0031, 0032, 0034 Coronary Artery Disease 0067, 0070, 0074 Diabetes 0055, 0056, 0059, 0061, 0062, 0064, 0575 Heart Failure 0081, 0083, 0084 Hypertension 0013, 0018 Immunization Status 0038, 0111, 0041 Ischemic Vascular Disease 0068, 0073, 0075 Prenatal Screening 0012, 0014 Smoking/Tobacco Use Assessment 0027, 0028a, 0028b Weight Assessment 0024, MicroMD EMR Clinical Quality Measure Calculations Version 7.5
14 REPORTING CLINICAL QUALITY MEASURES CHAPTER 2 NQF 0001 / PQRI 64 ASTHMA ASSESSMENT (ALTERNATE) Description: Clinical Rationale: Detail Percentage of patients aged 5 through 40 years with a diagnosis of asthma and who have been seen for at least two office visits, who were evaluated during at least one office visit within 12 months for the frequency (numeric) of daytime and nocturnal asthma symptoms. To determine whether the goals of therapy are being met, monitoring is recommended in the six areas listed below: Signs and symptoms (daytime; nocturnal awakening) of asthma Pulmonary function (spirometry; peak flow monitoring) Quality of life/functional status History of asthma exacerbations Pharmacotherapy (as-needed use of inhaled short-acting beta2- agonist, adherence to regimen of long-term-control medications) Patient-provider communication and patient satisfaction (NAEPP/NHLBI) Denominator: **Patients in Age Range: >= 5 and <=40 **who have condition of Asthma recorded in their chart-(see code list) Problem List Entry ( with a beginning date <= encounter date) or an Encounter Assessment (beginning date <= encounter date) AND **who have been seen at least two times **Date Range: during the reporting period Encounters with Encounter Levels specified. (see code list) Numerator: Exclusions: **Patients with Asthma History documented before the end of the reporting period. None. MedInfo>Histories> Asthma History Encounter Plan (QM Tab) in one encounter in the reporting period contains the following CPT code (1005F) MicroMD EMR Clinical Quality Measure Calculations Version
15 Code Lists for Measure Asthma ICD-9 Codes: (Denominator) Encounter Level Codes: (Denominator) Encounter Plan Codes: (Numerator) Detail , , , , , , , , , , , , , , 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99241, 99242, 99243, 99244, F NQF 0002 / PQRI 66 APPROPRIATE TESTING FOR CHILDREN WITH PHARYNGITIS (ALTERNATE) Description: Clinical Rationale: Detail The percentage of children 2-18 years of age who were diagnosed with Pharyngitis, dispensed an antibiotic and received a group A streptococcus (strep) test for the episode. This measure assesses the proportion of age-appropriate children diagnosed with pharyngitis who were prescribed an antibiotic at an outpatient visit and who received a group A streptococcus (group A strep) test. Pharyngitis occurs in all age groups, but those aged 5-18 years have the highest incidence of streptococcal infections. A physician s clinical diagnosis can be validated with an objective diagnostic (group A strep) test. This test, which is widely available to practitioners, can result in a reduction of two-thirds of antibiotic consumption of pharyngitis while maintaining significant benefits for patients. In a recent nationwide physician survey, however, 42% of physicians reported that they would start antibiotic treatment for children with pharyngitis before knowing the results of a group A strep test, and would continue treatment regardless. This measure is important because it requires initial antigen screening to ensure accurate diagnosis and promotes judicious use of antibiotics and reduction of antibiotic overuse. Denominator: **Patients in Age Range: >= 2 and <=18 **who have condition of Pharyngitis recorded in their chart- (see code list) MedInfo>Medical>Problem List Entry ( with a beginning date <= encounter date) or an Encounter with an Assessment (beginning date <= encounter date) AND **who have been seen at least 1 time during the reporting period (see code list) Encounters with Encounter Levels specified by ICD or CPT 2.2 MicroMD EMR Clinical Quality Measure Calculations Version 7.5
16 Detail AND ** who were prescribed medications for Pharyngitis (see code list) on the encounter date or up to 3 days afterwards. MedInfo>Medical>Medications - Medication for Pharyngitis AND NOT **Patients who were prescribed a qualifying antibiotic <=30 days prior to the encounter. MedInfo>Medical>Medications - Medication for Pharyngitis <= 30 days before 1 days prior to encounter. Numerator: Exclusions: Code Lists for Measure ICD-9 Codes: Pharyngitis (Denominator) Encounter Level Codes: (Denominator) **Patients who received a step test for the episode. Lab Test completed for LOINC Codes (see code list) Lab Test date is <= 3 days earlier than the medication given. None , 462, , 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99217, 99218, 99219, 99220, 99241, 99242, 99243, 99244, 99245, 99341, 99342, 99343, 99344, 99345, , 99384, 99385, 99386, 99387, 99394, 99395, 99396, 99397, 99401, 99402, 99403, 99404, 99411, 99412, 99420, 99429, 99455, 99456, 99281, 99282, 99283, 99284, Encounter Levels (Denominator) ICD Lab Result LOINC Codes: (Numerator) v70.0, v70.3, v70.5, v70.6, v70.8, v , , , , ,5036-9, 626-2, , , Qualifying Medications: A-Cillin 250 mg Cap, A-Cillin 500 mg Cap, Acanya 1.2 %-2.5 % Topical Gel, Achromycin 250 mg Cap, Achromycin V 125 mg/5 ml Oral Susp, Achromycin V 250 mg Cap, Achromycin V 500 mg Cap, Adoxa 100 mg Tab, Adoxa 150 mg Cap, Adoxa 50 mg Tab, Adoxa 75 mg Tab, Adoxa Pak 100 mg Tab, Adoxa Pak 150 mg Tab, Adoxa Pak 75 mg Tab, Ak-Ramycin 100 mg Cap, Ak-Ramycin 100 mg Tab, Ala-Tet 250 mg Cap, Alodox 20 mg Kit, Amcap 250 mg Cap, Amficot 250 mg Cap, amoxicillin 125 mg Chewable Tab, amoxicillin 125 mg/5 ml Oral Susp, amoxicillin 200 mg Chewable Tab, MicroMD EMR Clinical Quality Measure Calculations Version
17 amoxicillin 200 mg Dispersible Tab, amoxicillin 200 mg/5 ml Oral Susp, amoxicillin 250 mg Cap, amoxicillin 250 mg Chewable Tab, amoxicillin 250 mg/5 ml Oral Susp, amoxicillin 400 mg Chewable Tab, amoxicillin 400 mg Dispersible Tab, amoxicillin 400 mg/5 ml Oral Susp, amoxicillin 50 mg/ml Oral Susp, amoxicillin 500 mg Cap, amoxicillin 500 mg Tab, amoxicillin 600 mg Dispersible Tab, amoxicillin 875 mg Tab, amoxicillin ER 775 mg multiphase 24 hr Tab, amoxicillin-potassium clavulanate 125 mg mg Chewable Tab, amoxicillin-potassium clavulanate 125 mg mg/5 ml Oral Susp, amoxicillin-potassium clavulanate 200 mg-28.5 mg Chewable Tab, amoxicillin-potassium clavulanate 200 mg-28.5 mg/5 ml Oral Susp, amoxicillin-potassium clavulanate 250 mg-125 mg Tab, amoxicillinpotassium clavulanate 250 mg-62.5 mg Chewable Tab, amoxicillinpotassium clavulanate 250 mg-62.5 mg/5 ml Oral Susp, amoxicillinpotassium clavulanate 400 mg-57 mg Chewable Tab, amoxicillin-potassium clavulanate 400 mg-57 mg/5 ml Oral Susp, amoxicillin-potassium clavulanate 500 mg-125 mg Tab, amoxicillinpotassium clavulanate 600 mg-42.9 mg/5 ml Oral Susp, amoxicillinpotassium clavulanate 875 mg-125 mg Tab, amoxicillin-potassium clavulanate ER 1,000 mg-62.5 mg 12 hr Tab, Amoxil 125 mg Chewable Tab, Amoxil 125 mg/5 ml Oral Susp, Amoxil 200 mg Chewable Tab, Amoxil 200 mg/5 ml Oral Susp, Amoxil 250 mg Cap, Amoxil 250 mg Chewable Tab, Amoxil 250 mg/5 ml Oral Susp, Amoxil 400 mg Chewable Tab, Amoxil 400 mg/5 ml Oral Susp, Amoxil 50 mg/ml Oral Susp, Amoxil 500 mg Cap, Amoxil 500 mg Tab, Amoxil 875 mg Tab, Ampi-Co 125 mg/5 ml Oral Susp, Ampi-Co 250 mg Cap, Ampi-Co 250 mg/5 ml Oral Susp, Ampi-Co 500 mg Cap, Ampicap-S 125 mg/5 ml Oral Susp, Ampicap-S 250 mg Cap, Ampicap-S 250 mg/5 ml Oral Susp, ampicillin 1 gram IV Piggy Back, ampicillin 1 gram IV Solution, ampicillin 1 gram Solution for Injection, ampicillin 10 gram Solution for Injection, ampicillin 125 mg IV Solution, ampicillin 125 mg Solution for Injection, ampicillin 125 mg/5 ml Oral Susp, ampicillin 2 gram IV Piggy Back, ampicillin 2 gram IV Solution, ampicillin 2 gram Solution for Injection, ampicillin 250 mg Cap, ampicillin 250 mg IV Solution, ampicillin 250 mg Solution for Injection, ampicillin 250 mg/5 ml Oral Susp, ampicillin 500 mg Cap, ampicillin 500 mg IV Piggy Back, ampicillin 500 mg IV Solution, ampicillin 500 mg Solution for Injection, ampicillin-sulbactam 1.5 gram IV Piggy Back, ampicillin-sulbactam 1.5 gram IV Solution, ampicillin-sulbactam 1.5 gram Solution for Injection, ampicillinsulbactam 15 gram Solution for Injection, ampicillin-sulbactam 3 gram IV Piggy Back, ampicillin-sulbactam 3 gram IV Solution, ampicillin-sulbactam 3 gram Solution for Injection, Amplin 125 mg/5 ml Oral Susp, Amplin 250 mg Cap, Amplin 250 mg/5 ml Oral Susp, Amplin 500 mg Cap, Amplin mg/5 ml Oral Susp, Amplin mg Cap, Amplin mg/5 ml Oral Susp, Amplin mg Cap, Ancef 1 gram IV Piggy Back, Ancef 1 gram Solution for Injection, Ancef 10 gram Solution for Injection, Ancef MicroMD EMR Clinical Quality Measure Calculations Version 7.5
18 mg Solution for Injection, Ancef 5 gram Solution for Injection, Ancef 500 mg IV Piggy Back, Ancef 500 mg Solution for Injection, Ancef in dextrose (iso-osmotic) 1 gram/50 ml IV Piggy Back, Ancef in dextrose (iso-osmotic) 500 mg/50 ml IV Piggy Back, Anspor 125 mg/5 ml Oral Susp, Anspor 250 mg Cap, Anspor 250 mg/5 ml Oral Susp, Anspor 500 mg Cap, Aoracillin B 500 mg Tab, Arestin 1 mg Dental Cartridge, Arladox 100 mg Cap, Arladox 50 mg Cap, Augmentin 125 mg mg Chewable Tab, Augmentin 125 mg mg/5 ml Oral Susp, Augmentin 200 mg-28.5 mg Chewable Tab, Augmentin 200 mg-28.5 mg/5 ml Oral Susp, Augmentin 250 mg-125 mg Tab, Augmentin 250 mg-62.5 mg Chewable Tab, Augmentin 250 mg-62.5 mg/5 ml Oral Susp, Augmentin 400 mg-57 mg Chewable Tab, Augmentin 400 mg-57 mg/5 ml Oral Susp, Augmentin 500 mg-125 mg Tab, Augmentin 875 mg-125 mg Tab, Augmentin ES mg-42.9 mg/5 ml Oral Susp, Augmentin XR 1,000 mg-62.5 mg 12 hr Tab, Avelox 400 mg Tab, Avelox ABC Pack 400 mg Tab, Avelox in sodium chloride (iso-osmotic) 400 mg/250 ml IV Piggy Back, Avidoxy 100 mg Tab, azithromycin 1 gram Oral Packet, azithromycin 100 mg/5 ml Oral Susp, azithromycin 200 mg/5 ml Oral Susp, azithromycin 250 mg Cap, azithromycin 250 mg Tab, azithromycin 500 mg IV Solution, azithromycin ER 2 gram/60 ml Oral Susp, azithromycin hydrogen citrate 2.5 g IV Solution, azithromycin hydrogen citrate 500 mg IV Solution, Bactrim 200 mg-40 mg/5 ml Oral Susp, Bactrim 400 mg-80 mg Tab, Bactrim 400 mg-80 mg/5 ml IV, Bactrim DS 800 mg- 160 mg Tab, Beepen VK 125 mg/5 ml Oral Susp, Beepen VK 250 mg Tab, Beepen VK 250 mg/5 ml Oral Susp, Beepen-VK 500 mg Tab, Benzaclin 1 %-5 % Topical Gel, Benzaclin Carekit 1 %-5 % Topical Kit, Benzaclin Pump 1 %-5 % Topical Gel, Betapen VK 250 mg Tab, Betapen-VK 125 mg/5 ml Oral Susp, Betapen-VK 250 mg/5 ml Oral Susp, Betapen-VK 500 mg Tab, Bethaprim DS 800 mg-160 mg Tab, Biaxin 125 mg/5 ml Oral Susp, Biaxin mg/5 ml Oral Susp, Biaxin 250 mg Tab, Biaxin 250 mg/5 ml Oral Susp, Biaxin 500 mg Tab, Biaxin XL 500 mg 24 hr Tab, Biaxin XL Pak 500 mg 24 hr Tab, Bicillin C-R 1,200,000 unit/2 ml IM Syringe, Bicillin C-R 150,000 unit-150,000 unit/ml IM Susp, Bicillin C-R 900,000 unit-300k unit/2 ml IM Syringe, Bicillin L-A 1,200,000 unit/2 ml IM Syringe, Bicillin L-A 2,400,000 unit/4 ml IM Syringe, Bicillin L-A 300,000 unit/ml IM Susp, Bicillin L-A 600,000 unit/ml IM Syringe, Bio-Tab 100 mg Tab, Biocef 125 mg/5 ml Oral Susp, Biocef 250 mg/5 ml Oral Susp, Biocef 500 mg Cap, Biocycline 125 mg/5 ml Oral Susp, bismuth subcit K-metronidazole-tetracycline 140 mg-125 mg-125 mg Cap, Bristamycin 250 mg Tab, Brodspec 125 mg/5 ml Oral Susp, Brodspec 250 mg Cap, C-Lexin 250 mg Cap, C-Lexin 500 mg Cap, C/T/S 1 % Topical Soln, Caropen VK 250 mg Tab, Caropen-VK 125 mg/5 ml Oral Susp, Caropen-VK 250 mg/5 ml Oral Susp, Caropen-VK 500 mg Tab, Ceclor 125 mg/5 ml Oral Susp, Ceclor 187 mg/5 ml Oral Susp, Ceclor 250 mg Cap, Ceclor 250 mg/5 ml Oral Susp, Ceclor 375 mg/5 ml Oral Susp, Ceclor 500 MicroMD EMR Clinical Quality Measure Calculations Version
19 mg Cap, Ceclor CD 375 mg 12 hr Tab, Ceclor CD 500 mg 12 hr Tab, Cedax 180 mg/5 ml Oral Susp, Cedax 400 mg Cap, Cedax 90 mg/5 ml Oral Susp, cefaclor 125 mg Chewable Tab, cefaclor 125 mg/5 ml Oral Susp, cefaclor 187 mg Chewable Tab, cefaclor 187 mg/5 ml Oral Susp, cefaclor 250 mg Cap, cefaclor 250 mg Chewable Tab, cefaclor 250 mg/5 ml Oral Susp, cefaclor 375 mg Chewable Tab, cefaclor 375 mg/5 ml Oral Susp, cefaclor 500 mg Cap, cefaclor ER 375 mg 12 hr Tab, cefaclor ER 500 mg 12 hr Tab, cefadroxil 1 gram Tab, cefadroxil 125 mg/5 ml Oral Susp, cefadroxil 250 mg/5 ml Oral Susp, cefadroxil 500 mg Cap, cefadroxil 500 mg/5 ml Oral Susp, Cefanex 250 mg Cap, Cefanex 500 mg Cap, cefazolin 1 gram IV Piggy Back, cefazolin 1 gram IV Solution, cefazolin 1 gram Solution for Injection, cefazolin 10 gram Solution for Injection, cefazolin 100 gram Solution for Injection, cefazolin 20 gram Solution for Injection, cefazolin 250 mg Solution for Injection, cefazolin 300 g Solution for Injection, cefazolin 5 gram Solution for Injection, cefazolin 500 mg IV Piggy Back, cefazolin 500 mg Solution for Injection, cefazolin in 0.9 % sodium chloride 1 gram/10 ml IV Syringe, cefazolin in 0.9 % sodium chloride 2 gram/100 ml IV, cefazolin in D5W 2 gram/100 ml IV, cefazolin in dextrose (isoosmotic) 1 gram/50 ml IV Piggy Back, cefazolin in dextrose (iso-osmotic) 500 mg/50 ml IV Piggy Back, cefazolin sodium-sterile water 1 gram/10 ml IV Syringe, cefazolin sodium-sterile water 2 gram/20 ml IV Syringe, cefdinir 125 mg/5 ml Oral Susp, cefdinir 250 mg/5 ml Oral Susp, cefdinir 300 mg Cap, cefditoren pivoxil 200 mg Tab, cefditoren pivoxil 400 mg Tab, cefixime 100 mg/5 ml Oral Susp, cefixime 200 mg Tab, cefixime 200 mg/5 ml Oral Susp, cefixime 400 mg Tab, cefpodoxime 100 mg Tab, cefpodoxime 100 mg/5 ml Oral Susp, cefpodoxime 200 mg Tab, cefpodoxime 50 mg/5 ml Oral Susp, cefprozil 125 mg/5 ml Oral Susp, cefprozil 250 mg Tab, cefprozil 250 mg/5 ml Oral Susp, cefprozil 500 mg Tab, ceftibuten 180 mg/5 ml Oral Susp, ceftibuten 400 mg Cap, ceftibuten 90 mg/5 ml Oral Susp, Ceftin 125 mg Tab, Ceftin 125 mg/5 ml Oral Susp, Ceftin 250 mg Tab, Ceftin 250 mg/5 ml Oral Susp, Ceftin 500 mg Tab, ceftriaxone 1 gram IV Piggy Back, ceftriaxone 1 gram IV Solution, ceftriaxone 1 gram Solution for Injection, ceftriaxone 10 gram Solution for Injection, ceftriaxone 2 gram IV Piggy Back, ceftriaxone 2 gram IV Solution, ceftriaxone 2 gram Solution for Injection, ceftriaxone 250 mg Solution for Injection, ceftriaxone 500 mg Solution for Injection, ceftriaxone in dextrose (iso-osmotic) 1 gram/50 ml IV Piggy Back, ceftriaxone in dextrose (iso-osmotic) 2 gram/50 ml IV Piggy Back, cefuroxime axetil 125 mg Tab, cefuroxime axetil 125 mg/5 ml Oral Susp, cefuroxime axetil 250 mg Tab, cefuroxime axetil 250 mg/5 ml Oral Susp, cefuroxime axetil 500 mg Tab, cefuroxime in sterile water 1.5 gram/50 ml IV Piggy Back, cefuroxime sodium 1.5 gram IV Piggy Back, cefuroxime sodium 1.5 gram IV Solution, cefuroxime sodium 1.5 gram Solution for Injection, cefuroxime sodium 7.5 gram IV Solution, cefuroxime sodium in D5W 1.5 gram/100 ml IV Piggy Back, cefuroxime-dextrose (iso- 2.6 MicroMD EMR Clinical Quality Measure Calculations Version 7.5
20 osmotic) 1.5 gram/50 ml IV Piggy Back, cefuroxime-dextrose (iso-osmotic) 750 mg/50 ml IV Piggy Back, Cefzil 125 mg/5 ml Oral Susp, Cefzil 250 mg Tab, Cefzil 250 mg/5 ml Oral Susp, Cefzil 500 mg Tab, Cen-Amp 125 mg/5 ml Oral Susp, Cen-Amp 250 mg Cap, Cen-Amp 250 mg/5 ml Oral Susp, Cen-Mycin 250 mg Tab, Cen-Tet 250 mg Cap, Centet mg Cap, cephalexin 125 mg Dispersible Tab, cephalexin 125 mg/5 ml Oral Susp, cephalexin 250 mg Cap, cephalexin 250 mg Dispersible Tab, cephalexin 250 mg Tab, cephalexin 250 mg/5 ml Oral Susp, cephalexin 500 mg Cap, cephalexin 500 mg Tab, cephalexin 750 mg Cap, cephalexin HCl 500 mg Tab, cephradine 125 mg/5 ml Oral Susp, cephradine 250 mg Cap, cephradine 250 mg/5 ml Oral Susp, cephradine 500 mg Cap, Cheragan 500 mg Tab, Cheragan with Tmp 800 mg-160 mg Tab, Cipro 250 mg Tab, Cipro 250 mg/5 ml Oral Susp, Cipro 500 mg Tab, Cipro 500 mg/5 ml Oral Susp, Cipro 750 mg Tab, Cipro Cystitis 100 mg Tab, Cipro in D5W 200 mg/100 ml IV Piggy Back, Cipro in D5W 400 mg/200 ml IV Piggy Back, Cipro XR 1,000 mg 24 hr Tab, Cipro XR 500 mg 24 hr Tab, ciprofloxacin 100 mg Tab, ciprofloxacin 250 mg Tab, ciprofloxacin 250 mg/5 ml Oral Susp, ciprofloxacin 500 mg Tab, ciprofloxacin 500 mg/5 ml Oral Susp, ciprofloxacin 750 mg Tab, ciprofloxacin ER 1,000 mg multiphase 24 hr Tab, ciprofloxacin ER 500 mg 24 hr Tab, ciprofloxacin ER 500 mg multiphase 24 hr Tab, ciprofloxacin in D5W 200 mg/100 ml IV Piggy Back, ciprofloxacin in D5W 400 mg/200 ml IV Piggy Back, clarithromycin 125 mg/5 ml Oral Susp, clarithromycin mg/5 ml Oral Susp, clarithromycin 250 mg Tab, clarithromycin 250 mg/5 ml Oral Susp, clarithromycin 500 mg Tab, clarithromycin ER 500 mg 24 hr Tab, Cleocin 100 mg Vaginal Suppository, Cleocin 150 mg Cap, Cleocin 150 mg/ml Injection, Cleocin 2 % Vaginal Cream, Cleocin 300 mg Cap, Cleocin 600 mg/4 ml IV, Cleocin 75 mg Cap, Cleocin 75 mg/5 ml Oral Solution, Cleocin 900 mg/6 ml IV, Cleocin in D5W 300 mg/50 ml IV Piggy Back, Cleocin in D5W 600 mg/50 ml IV Piggy Back, Cleocin in D5W 900 mg/50 ml IV Piggy Back, Cleocin T 1 % Lotion, Cleocin T 1 % Soln, Cleocin T 1 % Topical Gel, Cleocin T 1 % Topical Swab, Clinda- Derm 1 % Topical Soln, Clindagel 1 % Topical, ClindaMax 1 % Lotion, ClindaMax 1 % Topical Gel, ClindaMax 2 % Vaginal Cream, clindamycin 1 % Lotion, clindamycin 1 % Topical Foam, clindamycin 1 % Topical Gel, clindamycin 1 % Topical Soln, Clindamycin 1 % Topical Swab, clindamycin 100 mg Vaginal Suppository, clindamycin 150 mg Cap, clindamycin 150 mg/ml Injection, clindamycin 2 % Vaginal Cream, clindamycin 300 mg Cap, clindamycin 300 mg/2 ml IV, clindamycin 600 mg/4 ml IV, clindamycin 75 mg Cap, clindamycin 75 mg/5 ml Oral Solution, clindamycin 900 mg/6 ml IV, clindamycin ER 2 % Vaginal Cream, clindamycin in D5W 300 mg/50 ml IV Piggy Back, clindamycin in D5W 600 mg/50 ml IV Piggy Back, clindamycin in D5W 900 mg/50 ml IV Piggy Back, clindamycin phosphate 1 % Topical Swab, clindamycin-benzoyl peroxide 1 %-5 % Topical Gel, clindamycin-benzoyl peroxide 1.2 %-2.5 % Topical Gel, clindamycin- MicroMD EMR Clinical Quality Measure Calculations Version
21 benzoyl peroxide ER 1 %-5 % Topical Gel, clindamycin-benzoyl peroxidehyaluronate 1 %-5 % Topical Kit, clindamycin-benzoyl peroxide-skin cleanser #5 1 %-5 % Topical Kit, clindamycin-tretinoin 1.2 % % Topical Gel, Clindesse 2 % Vaginal Cream, Clindets 1 % Topical Swab, Cofatrim Forte 800 mg-160 mg Tab, Colmox 250 mg Cap, Colmox 500 mg Cap, Comoxol 400 mg-80 mg Tab, Comoxol 800 mg-160 mg Tab, Cor Vk 250 mg/5 ml Oral Susp, Cotrim 200 mg-40 mg/5 ml Oral Susp, Cotrim 400 mg-80 mg Tab, Cotrim 400 mg-80 mg/5 ml IV, Cotrim Double-Strength 800 mg-160 mg Tab, Cotrim I.V. 400 mg-80 mg/5 ml Soln, Cyclatet 250 mg Cap, Cycline mg Cap, Cyclinex 250 mg Cap, D-Amp 500 mg Cap, D-Cillin 125 mg/5 ml Oral Susp, D-Cillin 250 mg Cap, D-Mycin 500 mg Cap, D-Sulfa 500 mg Tab, D.R. Erycin 250 mg Tab, D.R. T-Cycline 250 mg Cap, Deltamycin 250 mg Cap, Deltapen VK 250 mg Tab, Desamycin 250 mg Cap, Desamycin 500 mg Cap, dicloxacillin 250 mg Cap, dicloxacillin 500 mg Cap, dicloxacillin 62.5 mg/5 ml Oral Susp, DisperMox 200 mg Tab, DisperMox 400 mg Tab, DisperMox 600 mg Tab, Doryx 100 mg Cap, Doryx 100 mg Tab, Doryx 150 mg Tab, Doryx 75 mg Cap, Doryx 75 mg Tab, Doxi Film 100 mg Tab, Doxy 100 mg Cap, Doxy 100 mg Tab, Doxy mg IV Solution, Doxy mg IV Solution, Doxy-Caps 100 mg Cap, Doxy-Caps 50 mg Cap, Doxy-D 100 mg Cap, Doxy-D 50 mg Cap, Doxy-Lemmon 100 mg Cap, Doxy-Lemmon 100 mg Tab, Doxy- Lemmon 50 mg Cap, Doxy-Tabs 100 mg Tab, Doxychel 100 mg Cap, Doxychel 100 mg Tab, Doxychel 50 mg Cap, doxycycline 100 mg Cap, doxycycline 100 mg Tab, doxycycline 150 mg Cap, doxycycline 150 mg Tab, doxycycline 25 mg/5 ml Oral Susp, doxycycline 50 mg Cap, doxycycline 50 mg Tab, doxycycline 50 mg/5 ml Syrup, doxycycline 75 mg Cap, doxycycline 75 mg Tab, doxycycline hyclate 100 mg Cap, doxycycline hyclate 100 mg Cap, Delayed Release, doxycycline hyclate 100 mg IV Solution, doxycycline hyclate 100 mg Tab, doxycycline hyclate 100 mg Tab, Delayed Release, doxycycline hyclate 150 mg Tab, Delayed Release, doxycycline hyclate 20 mg Cap, doxycycline hyclate 20 mg Tab, doxycycline hyclate 200 mg IV Solution, doxycycline hyclate 50 mg Cap, doxycycline hyclate 75 mg Cap, Delayed Release, doxycycline hyclate 75 mg Tab, Delayed Release, doxycycline-eyelid cleansers no.2 & no.3 20 mg Kit, Doxygen 100 mg Tab, Duac 1 %-5 % Topical Gel, Duac CS 1 %-5 % Topical Kit, Duricef 1 gram Tab, Duricef 125 mg/5ml Oral Susp, Duricef 250 mg/5 ml Oral Susp, Duricef 500 mg Cap, Duricef 500 mg/5 ml Oral Susp, Dycill 250 mg Cap, Dycill 500 mg Cap, Dynacin 100 mg Cap, Dynacin 100 mg Tab, Dynacin 50 mg Cap, Dynacin 50 mg Tab, Dynacin 75 mg Cap, Dynacin 75 mg Tab, Dynapen 250 mg Cap, Dynapen 500 mg Cap, Dynapen 62.5 mg/5 ml Oral Susp, Dynasep DS 800 mg-160 mg Tab, Dynasep SS 400 mg-80 mg Tab, E- Base 500 mg Tab, E-Mycin E 200 mg/5 ml Oral Susp, E-Mycin E 400 mg/5 ml Oral Susp, E.E.S mg/5 ml Oral Susp, E.E.S mg/5 ml Susp, Recon, E.E.S. 200 mg Chewable Tab, E.E.S mg Tab, E.E.S. 2.8 MicroMD EMR Clinical Quality Measure Calculations Version 7.5
22 mg/5 ml Oral Susp, E.E.S. Granules 200 mg/5 ml Oral Susp, ED A- Ceph 125 mg/5 ml Oral Susp, ED A-Ceph 250 mg/5 ml Oral Susp, Emtet mg Cap, Entaceph 250 mg Cap, Entamox 250 mg Cap, Ery-Tab 500 mg Tab, EryPed 100 mg/2.5 ml Oral Drops, EryPed mg/5 ml Oral Susp, EryPed 200 mg Chewable Tab, EryPed 200 mg/5 ml Oral Susp, EryPed mg/5 ml Oral Susp, Erythro-C 250 mg Cap, Erythrobon 250 mg Tab, Erythrocin 1,000 mg IV Solution, Erythrocin 500 mg IV Piggy Back, Erythrocin 500 mg IV Solution, Erythrocin Lactobionate 500 mg IV Piggy Back, Erythrocin Stearate 250 mg Tab, Erythrocin Stearate 500 mg Tab, Erythrocot 250 mg Tab, erythromycin 500 mg Tab, erythromycin 500 mg Tab, Delayed Release, erythromycin 500 mg Tab, Particles/Crystals, erythromycin estolate 125 mg Chewable Tab, erythromycin estolate 125 mg/5 ml Oral Susp, erythromycin estolate 250 mg Cap, erythromycin estolate 250 mg Chewable Tab, erythromycin estolate 250 mg/5 ml Oral Susp, erythromycin estolate 500 mg Tab, erythromycin ethylsuccinate 100 mg/2.5 ml Oral Drops, erythromycin ethylsuccinate 200 mg Chewable Tab, erythromycin ethylsuccinate 200 mg/5 ml Oral Susp, erythromycin ethylsuccinate 200 mg/5 ml Susp, Recon, erythromycin ethylsuccinate 400 mg Tab, erythromycin ethylsuccinate 400 mg/5 ml Oral Susp, erythromycin ethylsuccinate 400 mg/5 ml Susp, Recon, erythromycin gluceptate 1 gram IV Solution, erythromycin lactobionate 1,000 mg IV Solution, erythromycin lactobionate 500 mg IV Piggy Back, erythromycin lactobionate 500 mg IV Solution, erythromycin stearate 250 mg Tab, erythromycin stearate 500 mg Tab, erythromycin-sulfisoxazole 200 mg-600 mg/5 ml Oral Susp, Erythrozone 125 mg/5 ml Oral Susp, Erythrozone 250 mg/5 ml Oral Susp, Eryzole 200 mg-600 mg/5 ml Oral Susp, Ethril mg Tab, Ethril mg Tab, Evoclin 1 % Topical Foam, Factive 320 mg Tab, Floxin 20 mg/ml IV, Floxin 200 mg Tab, Floxin 300 mg Tab, Floxin 40 mg/ml IV, Floxin 400 mg Tab, Floxin I.V. in D5W 200 mg/50 ml Piggy Back, Floxin I.V. in D5W 400 mg/100 ml Piggy Back, Gantrisin 500 mg Tab, Gantrisin 500 mg/5 ml Oral Susp, Gantrisin Pediatric 500 mg/5 ml Oral Susp, gatifloxacin 10 mg/ml IV, gatifloxacin 200 mg Tab, gatifloxacin 400 mg Tab, gatifloxacin in D5W 200 mg/100 ml IV Piggy Back, gatifloxacin in D5W 400 mg/200 ml IV Piggy Back, gemifloxacin 320 mg Tab, Gulfasin 500 mg Tab, Ilosone 125 mg Chewable Tab, Ilosone 125 mg/5 ml Oral Susp, Ilosone 250 mg Cap, Ilosone 250 mg Chewable Tab, Ilosone 250 mg/5 ml Oral Susp, Ilosone 500 mg Tab, Ilotycin 1 gram IV Solution, J-Azo 500 mg Tab, J-Cillin 250 mg Cap, J-Mycin 500 mg Cap, Keflet 250 mg Tab, Keflet 500 mg Tab, Keflex 125 mg/5 ml Oral Susp, Keflex 250 mg Cap, Keflex 250 mg/5 ml Oral Susp, Keflex 500 mg Cap, Keflex 750 mg Cap, Keftab 500 mg Tab, Kefurox 1.5 gram IV Piggy Back, Kefurox 1.5 gram IV Solution, Kefurox 1.5 gram Solution for Injection, Kefurox 7.5 gram IV Solution, Kefzol 1 gram IV Solution, Kefzol 1 gram Solution for Injection, Kefzol 10 gram Solution for Injection, Kefzol 20 gram MicroMD EMR Clinical Quality Measure Calculations Version
23 Solution for Injection, Kefzol 250 mg Solution for Injection, Kefzol 500 mg Solution for Injection, Kencillin mg Cap, Kenmycin mg Tab, Kidtrim DS 800 mg-160 mg Tab, Lanacillin VK 250 mg Tab, Lanacillin VK 500 mg Tab, Larotid 125 mg/5 ml Oral Susp, Larotid 250 mg Cap, Larotid 250 mg/5 ml Oral Susp, Larotid 50 mg/ml Oral Susp, Larotid 500 mg Cap, Ledercillin VK 125 mg/5 ml Oral Susp, Ledercillin VK 250 mg Tab, Ledercillin VK 250 mg/5 ml Oral Susp, Ledercillin VK 500 mg Tab, Levaquin 250 mg/10 ml Oral Soln, Levaquin 750 mg Tab, Levaquin in D5W 250 mg/50 ml IV Piggy Back, Levaquin in D5W 500 mg/100 ml IV Piggy Back, Levaquin in D5W 750 mg/150 ml IV Piggy Back, Levaquin Leva-Pak 750 mg Tab, levofloxacin 250 mg/10 ml Oral Soln, levofloxacin 750 mg Tab, levofloxacin in D5W 250 mg/50 ml IV Piggy Back, levofloxacin in D5W 500 mg/100 ml IV Piggy Back, levofloxacin in D5W 750 mg/150 ml IV Piggy Back, lomefloxacin 400 mg Tab, Lorabid 100 mg/5 ml Oral Susp, Lorabid 200 mg Cap, Lorabid 200 mg/5 ml Oral Susp, Lorabid 400 mg Cap, loracarbef 100 mg/5 ml Oral Susp, loracarbef 200 mg Cap, loracarbef 200 mg/5 ml Oral Susp, loracarbef 400 mg Cap, M-Amp 250 mg Cap, M-Mycin 250 mg Tab, M-Tet 250 mg Cap, M-Tetra mg Cap, Marcillin 125 mg/5 ml Oral Susp, Marcillin 250 mg Cap, Marcillin 250 mg/5 ml Oral Susp, Marcillin 500 mg Cap, Marpen VK 125 mg/5 ml Oral Susp, Marpen VK 250 mg Tab, Marpen VK 250 mg/5 ml Oral Susp, Martet 250 mg Cap, Martet 500 mg Cap, Maxaquin 400 mg Tab, Minocin 100 mg Cap, Minocin 100 mg Combo Pack, Minocin 100 mg IV Solution, Minocin 50 mg Cap, Minocin 50 mg Combo Pack, Minocin 50 mg/5ml Oral Susp, minocycline 100 mg Cap, minocycline 100 mg IV Solution, minocycline 100 mg Tab, minocycline 50 mg Cap, minocycline 50 mg Tab, minocycline 50 mg/5 ml Oral Susp, minocycline 75 mg Cap, minocycline 75 mg Tab, minocycline ER 115 mg 24 hr Tab, minocycline ER 135 mg 24 hr Tab, minocycline ER 45 mg 24 hr Tab, minocycline ER 65 mg 24 hr Tab, minocycline ER 90 mg 24 hr Tab, minocycline microspheres 1 mg Dental Cartridge, minocycline-wipes 100 mg Combo Pack, minocycline-wipes 50 mg Combo Pack, Monodox 100 mg Cap, Monodox 50 mg Cap, Monodox 75 mg Cap, Mox-I mg/5 ml Oral Susp, Moxatag 775 mg 24 hr Tab, moxifloxacin 400 mg Tab, moxifloxacin in sodium chloride (iso-osm) 400 mg/250 ml IV Piggy Back, Moxilin 250 mg Cap, Moxilin 250 mg/5 ml Oral Susp, Moxilin 500 mg Cap, My-E 250 mg Tab, My-E Film 250 mg Tab, My-E Film 500 mg Tab, Nor-Tet 250 mg Cap, norfloxacin 400 mg Tab, Noroxin 400 mg Tab, Nortet 500 mg Cap, ofloxacin 20 mg/ml IV, ofloxacin 200 mg Tab, ofloxacin 300 mg Tab, ofloxacin 40 mg/ml IV, ofloxacin 400 mg Tab, ofloxacin in D5W 200 mg/50 ml IV Piggy Back, ofloxacin in D5W 400 mg/100 ml IV Piggy Back, Omnicef 125 mg/5 ml Oral Susp, Omnicef 250 mg/5 ml Oral Susp, Omnicef 300 mg Cap, Omnipen 125 mg/5 ml Oral Susp, Omnipen 250 mg Cap, Omnipen 250 mg/5 ml Oral Susp, Omnipen 500 mg Cap, Omnipen Redipak 250 mg Cap, Omnipen Redipak 500 mg Cap, Omnipen-N 1 gram IV Piggy Back, 2.10 MicroMD EMR Clinical Quality Measure Calculations Version 7.5
24 Omnipen-N 1 gram IV Solution, Omnipen-N 1 gram Solution for Injection, Omnipen-N 10 gram Solution for Injection, Omnipen-N 125 mg Solution for Injection, Omnipen-N 2 gram IV Piggy Back, Omnipen-N 2 gram IV Solution, Omnipen-N 2 gram Solution for Injection, Omnipen-N 250 mg Solution for Injection, Omnipen-N 500 mg IV Piggy Back, Omnipen-N 500 mg Solution for Injection, Oraxyl 20 mg Cap, Panixine DisperDose 125 mg Tab, Panixine DisperDose 250 mg Tab, Panmycin 250 mg Cap, Panmycin 250 mg Tab, Panmycin 500 mg Tab, Panmycin Syrup 125 mg/5 ml Oral Susp, Pathocil 250 mg Cap, Pathocil 500 mg Cap, Pathocil 62.5 mg/5 ml Oral Susp, PC Mycin 250 mg Tab, PC Pen V K 500 mg Tab, Pc Pen VK 250 mg Tab, PC Tet 250 mg Cap, PC Tet 500 mg Cap, PCE 500 mg Tab, Pediamycin 200 mg Chewable Tab, Pediamycin 200 mg/5 ml Oral Susp, Pediamycin 400 mg/5 ml Oral Susp, Pediatrim 200 mg-40 mg/5 ml Oral Susp, Pediazole 200 mg-600 mg/5 ml Oral Susp, Pen-Vee K 125 mg/5 ml Oral Susp, Pen-Vee K 250 mg Tab, Pen-Vee K 250 mg/5 ml Oral Susp, Pen- Vee K 500 mg Tab, Penamp mg Cap, Penamp mg Cap, penicillin G benzathine 1,200,000 unit/2 ml IM Syringe, penicillin G benzathine 2,400,000 unit/4 ml IM Syringe, penicillin G benzathine 300,000 unit/ml IM Susp, penicillin G benzathine 600,000 unit/ml IM Syringe, penicillin G benzathine&procain 1,200,000 unit/2 ml IM Syringe, penicillin G benzathine&procain 150,000 unit-150,000 unit/ml IM Susp, penicillin G benzathine&procain 900,000 unit-300k unit/2 ml IM Syringe, penicillin G pot in dextrose 1 million unit/50 ml IV Piggy Back, penicillin G pot in dextrose 2 million unit/50 ml IV Piggy Back, penicillin G pot in dextrose 3 million unit/50 ml IV Piggy Back, penicillin G potassium 1 million unit Solution for Injection, penicillin G potassium 10 million unit Solution for Injection, penicillin G potassium 20 million unit Solution for Injection, penicillin G potassium 5 million unit Solution for Injection, penicillin G potassium in D5W 1 million unit/50 ml IV Piggy Back, penicillin G potassium in D5W 2 million unit/50 ml IV Piggy Back, penicillin G potassium in D5W 3 million unit/100 ml IV Piggy Back, penicillin G procaine 1,200,000 unit IM Syringe, penicillin G procaine 300,000 unit/ml IM Susp, penicillin G procaine 600,000 unit IM Syringe, penicillin G sodium 5 million unit Solution for Injection, penicillin V potassium 125 mg/5 ml Oral Susp, penicillin V potassium 250 mg Tab, penicillin V potassium 250 mg/5 ml Oral Susp, penicillin V potassium 500 mg Tab, Pensyn 500 mg Cap, Periostat 20 mg Cap, Periostat 20 mg Tab, Permapen 1,200,000 unit/2 ml IM Syringe, Pfizer-E 250 mg Tab, Pfizer-E 500 mg Tab, Pfizerpen 5 million unit Solution for Injection, Pfizerpen A 125 mg/5 ml Oral Susp, Pfizerpen A 250 mg Cap, Pfizerpen A 250 mg/5 ml Oral Susp, Pfizerpen A 500 mg Cap, Pfizerpen-AS 300,000 unit/ml IM Susp, Pfizerpen-G 20 million unit Solution for Injection, Pfizerpen-G 5 million unit Solution for Injection, Piracaps 500 mg Cap, Poly-V 100 mg Tab, Polycillin 125 mg/5 ml Oral Susp, Polycillin 250 mg Cap, Polycillin 250 mg/5 ml Oral Susp, MicroMD EMR Clinical Quality Measure Calculations Version
25 Polycillin 500 mg Cap, Polycillin Dosa-Trol 250 mg/5 ml Oral Susp, Polycillin-N 1 gram IV Piggy Back, Polycillin-N 10 gram Solution for Injection, Polycillin-N 2 gram Solution for Injection, Polycillin-N 250 mg Solution for Injection, Polycillin-N 500 mg Solution for Injection, Polymox 125 mg/5 ml Oral Susp, Polymox 250 mg Cap, Polymox 250 mg/5 ml Oral Susp, Polymox 50 mg/ml Oral Susp, Polymox 500 mg Cap, Polymyxin B Sul- Trimethoprim 0.1 %-10,000 unit/ml Eye Drops, Polytrim 0.1 %-10,000 unit/ml Eye Drops, Primsol 50 mg/5 ml Oral Soln, Principen mg/5 ml Oral Susp, Principen 125 mg/5 ml Oral Susp, Principen mg Cap, Principen mg/5 ml Oral Susp, Principen 250 mg Cap, Principen 250 mg/5 ml Oral Susp, Principen mg Cap, Principen 500 mg Cap, Proloprim 100 mg Tab, Proloprim 200 mg Tab, ProQuin XR 500 mg 24 hr Tab, Pylera 140 mg-125 mg-125 mg Cap, Q- Amp 250 mg Cap, Rancillin 250 mg Cap, Rancillin 500 mg Cap, Raniclor 125 mg Chewable Tab, Raniclor 187 mg Chewable Tab, Raniclor 250 mg Chewable Tab, Raniclor 375 mg Chewable Tab, Retet 250 mg Cap, Retet mg Cap, Robicillin VK 250 mg Tab, Robicillin VK 500 mg Tab, Robitet 250 mg Cap, Robitet 500 mg Cap, Rocephin 1 gram IV Piggy Back, Rocephin 1 gram IV Solution, Rocephin 1 gram Solution for Injection, Rocephin 10 gram Solution for Injection, Rocephin 2 gram IV Piggy Back, Rocephin 2 gram IV Solution, Rocephin 2 gram Solution for Injection, Rocephin 250 mg Solution for Injection, Rocephin 500 mg Solution for Injection, Rocephin in dextrose (iso-osmotic) 1 gram/50 ml IV Piggy Back, Rocephin in dextrose (iso-osmotic) 2 gram/50 ml IV Piggy Back, Sarocycline 250 mg Cap, Senox 250 mg Cap, Septra 200 mg-40 mg/5 ml Oral Susp, Septra 400 mg-80 mg Tab, Septra DS 800 mg-160 mg Tab, Septra I.V. 400 mg-80 mg/5 ml Soln, Sk-Ampicillin Trihydrate 125 mg/5 ml Oral Susp, Sk- Ampicillin Trihydrate 250 mg/5 ml Oral Susp, Sk-Ampicillin-N 500 mg Solution for Injection, Sk-Doxycycline Hyclate 100 mg Cap, Sk-Doxycycline Hyclate 50 mg Cap, Sk-Erythromycin 250 mg Tab, Sk-Erythromycin 500 mg Tab, Sk-Soxazole 500 mg Tab, SK-Tetracycline 125 mg/5 ml Oral Susp, SK- Tetracycline 250 mg Cap, SK-Tetracycline 500 mg Cap, SMZ-TMP DS 800 mg-160 mg Tab, Solodyn 115 mg 24 hr Tab, Solodyn 135 mg 24 hr Tab, Solodyn 45 mg 24 hr Tab, Solodyn 65 mg 24 hr Tab, Solodyn 90 mg 24 hr Tab, Soxa 500 mg Tab, sparfloxacin 200 mg Tab, Spectracef 200 mg Tab, Spectracef 400 mg Tab, Sulfagan 500 mg Tab, Sulfamar 200 mg-40 mg/5 ml Oral Susp, Sulfamethoprim 400 mg-80 mg Tab, Sulfamethoprim 400 mg-80 mg/5 ml IV, Sulfamethoprim DS 800 mg-160 mg Tab, Sulfamethoprim SS 400 mg-80 mg Tab, sulfamethoxazole-trimethoprim 200 mg-40 mg/5 ml Oral Susp, sulfamethoxazole-trimethoprim 400 mg-80 mg Tab, sulfamethoxazole-trimethoprim 400 mg-80 mg/5 ml IV, sulfamethoxazole-trimethoprim 80 mg-16 mg/ml IV Syringe, sulfamethoxazole-trimethoprim 800 mg-160 mg Tab, Sulfaprim 200 mg-40 mg/5 ml Oral Susp, Sulfaprim 400 mg-80 mg Tab, Sulfaprim DS 800 mg MicroMD EMR Clinical Quality Measure Calculations Version 7.5
Demonstrating Meaningful Use Stage 1 Requirements for Eligible Providers Using Certified EMR Technology
Demonstrating Meaningful Use Stage 1 Requirements for Eligible Providers Using Certified EMR Technology The chart below lists the measures (and specialty exclusions) that eligible providers must demonstrate
More informationPsychiatrists and Reporting on Meaningful Use Stage 1. August 6, 2012
Psychiatrists and Reporting on Meaningful Use Stage 1 August 6, 2012 Quick Overview Functional Measures Providers (tracked by NPI) must report on 15 core objectives and associated measures and 5 objectives
More informationClinical Quality Measure Crosswalk: HEDIS, Meaningful Use, PQRS, PCMH, Beacon, 10 SOW
Clinical Crosswalk: HEDIS, Meaningful Use, PQRS, PCMH, Beacon, 10 SOW NQF 0105 PQRS 9 NQF 0002 PQRS 66 Antidepressant Medication Management Appropriate Testing for Children with Pharyngitis (2-18 years)
More informationRadiology Business Management Association Technology Task Force. Sample Request for Proposal
Technology Task Force Sample Request for Proposal This document has been created by the RBMA s Technology Task Force as a guideline for use by RBMA members working with potential suppliers of Electronic
More informationStage 1 Meaningful Use for Specialists. NYC REACH Primary Care Information Project NYC Department of Health & Mental Hygiene
Stage 1 Meaningful Use for Specialists NYC REACH Primary Care Information Project NYC Department of Health & Mental Hygiene 1 Today s Agenda Meaningful Use Overview Meaningful Use Measures Resources Primary
More informationMedicare & Medicaid EHR Incentive Program Meaningful Use Stage 1 Requirements Summary. http://www.cms.gov/ehrincentiveprograms/
Medicare & Medicaid EHR Incentive Program Meaningful Use Stage 1 Requirements Summary 2010 What are the Requirements of Stage 1 Meaningful Use? Basic Overview of Stage 1 Meaningful Use: Reporting period
More information2012 Physician Quality Reporting System:
DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services R Official CMS Information for Medicare Fee-For-Service Providers 2012 Physician Quality : Medicare Electronic Health Record
More informationAppropriate Treatment for Children with Upper Respiratory Infection
BCBS ACO Measure Appropriate Treatment for Children with Upper Respiratory Infection HEDIS Measure CPT II coding required: YES Click here to go to Table of Contents BCBS Measure: Page 50 of 234 Dated:
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #65 (NQF 0069): Appropriate Treatment for Children with Upper Respiratory Infection (URI) National Quality Strategy Domain: Efficiency and Cost Reduction 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES:
More informationOverview of Clinical Quality Measures Reporting in the Centers for Medicare & Medicaid Services (CMS) Final Rule on Meaningful Use
Overview of Clinical Quality Measures Reporting in the Centers for Medicare & Medicaid Services (CMS) Final Rule on Meaningful Use Clinical Quality Measures Clinical quality measures have been defined
More informationMedicare EHR Incentive Program - Meaningful Use
EHR Incentive Programs A program administered by the Centers for Medicare & Medicaid Services (CMS) An Introduction to the Medicare EHR Incentive Program for Eligible Professionals cms.gov/ehrincentiveprograms
More informationAn Introduction to the Medicare EHR Incentive Program for Eligible Professionals
EHR Incentive Programs A program administered by the Centers for Medicare & Medicaid Services (CMS) An Introduction to the Medicare EHR Incentive Program for Eligible Professionals cms.gov/ehrincentiveprograms
More informationElectronic Medical Records Meaningful Use Guide TABLE OF CONTENTS. Master Files to Update...2. Prepare Superbill Encounter Forms...
AMS Electronic Medical Records Meaningful Use Guide TABLE OF CONTENTS Master Files to Update...2 Prepare Superbill Encounter Forms...3 Patient Presents to Check In...3 Clinical Staff is Ready for Next
More informationMICROMD EMR VERSION 9.0 2014 OBJECTIVE MEASURE CALCULATIONS
MICROMD EMR VERSION 9.0 2014 OBJECTIVE MEASURE CALCULATIONS TABLE OF CONTENTS PREFACE Welcome to MicroMD EMR... i How This Guide is Organized... i Understanding Typographical Conventions... i Cross-References...
More informationPrimary Care in the U.S. Measuring and Improving Primary Care in the United States ISQua Indicators Summit 2012. CMS Measures. Primary Care Measures
Primary Care in the U.S. Measuring and Improving Primary Care in the United States ISQua Indicators Summit 2012 Cliff Fullerton, MD, MS VP Chronic Disease Baylor Health Care System Number of PCPs in the
More informationMicroMD EMR version 7.6
MicroMD EMR version 7.6 H I T E C H M E A S U R E C a l c u l a t i o n s MICROMD EMR HITECH MEASURE CALCULATIONS VERSION 7.6 TABLE OF CONTENTS PREFACE Welcome to MicroMD EMR... i How This Guide is Organized...
More informationStage 2 June 13, 2014
Stage 2 June 13, 2014 1 General Overview of Idaho Medicaid s EHR Incentive Program Stage 2 Meaningful Use (MU) Overview 2014 Reporting Helpful Resources 2 3 Medicaid can pay certain providers an incentive
More informationTest Procedure for 170.304 (j) Calculate and Submit Clinical Quality Measures
Test Procedure for 170.304 (j) Calculate and Submit Clinical Quality Measures This document describes the draft test procedure for evaluating conformance of complete EHRs or EHR modules 1 to the certification
More informationMedicare & Medicaid EHR Incentive Programs. Specifics of the Program for Eligible Professionals
Medicare & Medicaid EHR Incentive Programs Specifics of the Program for Eligible Professionals Today s Session This training will cover the following topics: EHR Incentive Programs a Background Who Is
More informationCore Set of Objectives and Measures Must Meet All 15 Measures Stage 1 Objectives Stage 1 Measures Reporting Method
Stage 1 Meaningful Use Criteria Physicians must meet all 15 Core Set objectives and measures and five of the 10 Menu Set objectives and measures. They also must report clinical quality measures (see separate
More informationOrchard Software Webinar August 19, 2010. Slide 1
Slide 1 An Update on ARRA and Its Impact on Laboratories Presented By: Curt Johnson VP of Sales & Marketing cjohnson@orchardsoft.com www.orchardsoft.com (800) 856-1948 Orchard Software Webinar August 19,
More informationMeaningful Use: Stage 1: Functional Measures Eligible Professionals (EPs)
Meaningful Use: Stage 1: Functional Measures Eligible Professionals (EPs) What is Meaningful Use? American Recovery and Reinvestment Act of 2009/Health Information Technology for Economic and Clinical
More informationMedicare & Medicaid EHR Incentive Program Meaningful Use Stage 1 Requirements Overview. http://www.cms.gov/ehrincentiveprograms/
Medicare & Medicaid EHR Incentive Program Meaningful Use Stage 1 Requirements Overview 2010 What is Meaningful Use? Meaningful Use is using certified EHR technology to Improve quality, safety, efficiency,
More informationWe're Ready for MU2...Are You?
Meaningful Use Are you considering purchasing an Electronic Health Record (EHR) or moving from your current vendor? Is your goal to attain Meaningful Use status in order to receive EHR incentive dollars?
More information12/15/2010. EMR Incentive Program for Eligible Professionals
12/15/2010 EMR Incentive Program for Eligible Professionals Topics for Today Meaningful Use Program Overview Who is eligible What is Meaningful Use (MU) How do you qualify How do you sign up How to determine
More informationMedical Billing Requirements - Medicaid Incentive Checklist
AAP Meaningful Use: Becoming a Meaningful User An Outpatient Checklist On July 13, 2010, the US Centers for Medicare and Medicaid Services (CMS) released a Final Rule establishing the criteria with which
More informationMeaningful Use. Relevance. What is ARRA Meaningful Use? (American Recovery and Reinvestment Act of 2009)
Meaningful Use First The What, Now The How S. Hughes Melton, MD President, C-Health, P.C. hmelton@c-healthonline.com Relevance Speedometer, Consumer Reports Your Teenager Provider A and B Google: Rate
More informationMedicare & Medicaid EHR Incentive Program Specifics of the Program for Eligible Professionals. August 10, 2010
Medicare & Medicaid EHR Incentive Program Specifics of the Program for Eligible Professionals August 10, 2010 Today s Session This training will cover the following topics: EHR Incentive Programs a Background
More informationTeasing Some Meaning Out of Meaningful Use
Teasing Some Meaning Out of Meaningful Use An Overview Colorado Bar Association, Health Law Section December 15, 2010 Steve Nash, Partner SNash@PattonBoggs.com Melodi (Mel) Mosley Gates MGates@PattonBoggs.com
More informationClinical Quality Measures. for 2014
Clinical Quality Measures for 2014 Mission of OFMQHIT To advance the implementation and use of vital health information technology to improve healthcare quality, efficiency and safety by assisting physician
More informationMany of the changes that have been made to this final rule were directly responsive to CMA s comments.
On July 13, 2010, the Centers for Medicare & Medicaid Services (CMS) released the final rule defining meaningful use of an electronic health record (EHR) system. The original version of this rule was released
More informationFoundations for Achieving Meaningful Use and Breaking Down EHR Barriers
Foundations for Achieving Meaningful Use and Breaking Down EHR Barriers Prepared by: Coker Group Physicians Institute 1849 The Exchange Atlanta, GA 30339 A BOUT THE PHYSICIANS INSTITUTE The Physicians'
More informationMedicare & Medicaid EHR Incentive Program Final Rule
Medicare & Medicaid EHR Incentive Program Final Rule Implementing the American Recovery and Reinvestment Act of 2009 Presented by: Kevin R. Burchill, Esq., FACHE Director Date: August 19, 2010 Overview
More informationMeaningful Use: Making use of Clinical Decision Support. Matt Allison
Meaningful Use: Making use of Clinical Decision Support Matt Allison Preparing for Meaningful Use ARRA/HITECH Goals Overview Final Rule for MU Stage 1 Medicare Program Utilizing Clinical Decision Support
More informationDrug Use Review. Edward Cox, M.D. Director Office of Antimicrobial Products
Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Drug Use Review Date: April 5, 2012 To: Through: Edward Cox, M.D. Director
More informationDate: November 30, 2010
Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Date: November 30, 2010 To: Through: From: Subject: Drug Name(s): Application
More informationInteGreat EHR Meaningful Use 2 Features and Reports Jenni Walters, Sr. Business Analyst, McKesson Beth Crews, Business Analyst, McKesson
InteGreat EHR Meaningful Use 2 Features and Reports Jenni Walters, Sr. Business Analyst, McKesson Beth Crews, Business Analyst, McKesson Stage 2 Overview On September 4, 2012, CMS published final rule
More information2013 ACO Quality Measures
ACO 1-7 Patient Satisfaction Survey Consumer Assessment of HealthCare Providers Survey (CAHPS) 1. Getting Timely Care, Appointments, Information 2. How well Your Providers Communicate 3. Patient Rating
More informationDashboard Overview Webinar
Regional Information for Shared Excellence (RISE) Initiative Dashboard Overview Webinar Jerry Lassa, MS Statistics May 15 & May 17, 2012 Do You Ever Spend a lot of time reviewing data trying to make sense
More informationHEdis Code Quick Reference Guide Disease Management Services
HEdis Code Quick Reference Guide Disease Management Services Respiratory Conditions Appropriate Testing for Children With Pharyngitis (ages 2-18) [Commercial, Medicaid] Appropriate Treatment (no antibiotic)
More information11/2/2015 Domain: Care Coordination / Patient Safety
11/2/2015 Domain: Care Coordination / Patient Safety 2014 CT Commercial Medicaid Compared to 2012 all LOB Medicaid Quality Compass Benchmarks 2 3 4 5 6 7 8 9 10 Documentation of Current Medications in
More information2010 QARR QUICK REFERENCE GUIDE Adults
2010 QARR QUICK REFERENCE GUIDE Adults ADULT MEASURES (19 through 64 years) GUIDELINE HEDIS COMPLIANT CPT/ICD9 CODES DOCUMENTATION TIPS Well Care Access to Ambulatory Care Ensure a preventive or other
More informationWelcome to the Data Analytics Toolkit PowerPoint presentation on clinical quality measures, meaningful use, and data analytics.
Welcome to the Data Analytics Toolkit PowerPoint presentation on clinical quality measures, meaningful use, and data analytics. According to the Centers for Medicare and Medicaid Services, Clinical Quality
More informationPerformance Measurement for the Medicare and Medicaid Eligible (MME) Population in Connecticut Survey Analysis
Performance Measurement for the Medicare and Medicaid Eligible (MME) Population in Connecticut Survey Analysis Methodology: 8 respondents The measures are incorporated into one of four sections: Highly
More informationABELMed EHR-EMR/PM version 12, an ONC HIT 2014 Edition Complete EHR, has been certified for the following 42 clinical quality measures (CQMs).
ABELMed EHR-EMR/PM version 12, an ONC HIT 2014 Edition Complete EHR, has been certified for the following 42 clinical quality measures (CQMs). The information contained in this document is also available
More informationImproving Quality of Care for Medicare Patients: Accountable Care Organizations
DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services Improving Quality of Care for Medicare Patients: FACT SHEET Overview http://www.cms.gov/sharedsavingsprogram On October
More informationMEANINGFUL USE STAGE 2 2015 FOR ELIGIBLE PROVIDERS USING CERTIFIED EMR TECHNOLOGY
MEANINGFUL USE STAGE 2 2015 FOR ELIGIBLE PROVIDERS USING CERTIFIED EMR TECHNOLOGY STAGE 2 REQUIREMENTS EPs must meet or qualify for an exclusion to 17 core objectives EPs must meet 3 of the 6 menu measures.
More informationOphthalmology Meaningful Use Attestation Guide Stage 1 2013 Edition
Ophthalmology Meaningful Use Attestation Guide Stage 1 2013 Edition Ophthalmologists can register for the Medicare electronic health record (EHR) incentive program on the CMS website: https://ehrincentives.cms.gov
More informationDEMONSTRATING MEANINGFUL USE STAGE 1 REQUIREMENTS FOR ELIGIBLE PROVIDERS USING CERTIFIED EHR TECHNOLOGY IN 2015
DEMONSTRATING MEANINGFUL USE STAGE 1 REQUIREMENTS FOR ELIGIBLE PROVIDERS USING CERTIFIED EHR TECHNOLOGY IN 2015 The chart below lists the measures (and specialty exclusions) that eligible providers must
More informationCQMs. Clinical Quality Measures 101
CQMs Clinical Quality Measures 101 BASICS AND GOALS In the past 10 years, clinical quality measures (CQMs) have become an integral component in the Centers for Medicare & Medicaid Services (CMS) drive
More informationHEDIS/CAHPS 101. August 13, 2012 Minnesota Measurement and Reporting Workgroup
HEDIS/CAHPS 101 Minnesota Measurement and Reporting Workgroup Objectives Provide introduction to NCQA Identify HEDIS/CAHPS basics Discuss various components related to HEDIS/CAHPS usage, including State
More informationDEMONSTRATING MEANINGFUL USE STAGE 1 REQUIREMENTS FOR ELIGIBLE PROVIDERS USING CERTIFIED EHR TECHNOLOGY IN 2014
DEMONSTRATING MEANINGFUL USE STAGE 1 REQUIREMENTS FOR ELIGIBLE PROVIDERS USING CERTIFIED EHR TECHNOLOGY IN 2014 The chart below lists the measures (and specialty exclusions) that eligible providers must
More informationNCQA Health Insurance Plan Ratings Methodology March 2015
NCQA Health Insurance Plan Ratings Methodology March 205 REVISION CHART Date Published March 205 Description Final version (next update will be based on the 50% measure exclusion rule) TABLE OF CONTENTS
More informationMeaningful Use - Stage 1. And. Practice Maximus
Meaningful Use - Stage 1 And Practice Maximus The following explains how Practice Maximus certified EHR module allows user to achieve meaningful use objectives for Stage 1. Eligible Professionals (EP)
More informationUnderstanding how to use the Quality Measure Step by Step Documents
Understanding how to use the Quality Measure Step by Step Documents Step 1: Quality Measure Selection o The first step for Quality Measures is to ensure you know what the measures are looking for from
More informationMicroMD EMR version 7.5. update GUIDE
MicroMD EMR version 7.5 update GUIDE THIS PAGE INTENTIONALLY LEFT BLANK MICROMD EMR UPDATE GUIDE VERSION 7.5 TRADEMARKS Because of the nature of the material, numerous hardware and software products are
More informationPROGRAM ASSISTANCE LETTER
PROGRAM ASSISTANCE LETTER DOCUMENT NUMBER: PAL 2012-03 DATE: April 11, 2012 DOCUMENT TITLE: Approved Uniform Data System Changes for 2012 TO: Health Center Program Grantees Primary Care Associations Primary
More informationMEANINGFUL USE STAGE 2 REQUIREMENTS FOR ELIGIBLE PROVIDERS USING CERTIFIED EMR TECHNOLOGY
MEANINGFUL USE STAGE 2 REQUIREMENTS FOR ELIGIBLE PROVIDERS USING CERTIFIED EMR TECHNOLOGY On August 24, the Centers for Medicare & Medicaid Services (CMS) posted the much anticipated final rule for Stage
More informationImproving Quality of Care for Medicare Patients: Accountable Care Organizations
DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services Improving Quality of Medicare Patients: Overview The Centers for Medicare & Medicaid Services (), an agency within the Department
More informationA Detailed Data Set From the Year 2011
2012 HEDIS 2012 A Detailed Data Set From the Year 2011 Commercial Product We are pleased to present the AvMed HEDIS 2012 Report, a detailed data set designed to give employers and consumers an objective
More informationSUMMARY TABLE OF MEASURE CHANGES
SUMMARY TABLE OF MEASURE CHANGES Measure Name Effectiveness of Preventive Care Adult BMI Assessment Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents Childhood
More informationPrimary Care Quality Care Indicators - Accuro EMR Prevention
Quality Indicators Primary Care Quality Care Indicators - Accuro EMR Prevention Data needs to be entered as indicated in order to auto populate the worksheet Date of colon cancer screening Exemption from
More informationPrescription Drug Guide
2012 Prescription Drug Guide Humana Group Medicare Formulary List of covered drugs Humana Group Medicare Plus 3 PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN. Y0040_PDG12b_Final_522C
More informationWHAT ARE CLINICAL QUALITY MEASURES? IMPORTANT TERMS
Practice Fusion 2014 Clinical Quality Measure Guide This guide will provide in depth information on the clinical quality measures that are available in Practice Fusion. WHAT ARE CLINICAL QUALITY MEASURES?
More informationTable 1 Performance Measures. Quality Monitoring P4P Yr1 Yr2 Yr3. Specification Source. # Category Performance Measure
Table 1 Performance Measures # Category Performance Measure 1 Behavioral Health Risk Assessment and Follow-up 1) Behavioral Screening/ Assessment within 60 days of enrollment New Enrollees who completed
More informationMar. 31, 2011 (202) 690-6145. Improving Quality of Care for Medicare Patients: Accountable Care Organizations
DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services Room 352-G 200 Independence Avenue, SW Washington, DC 20201 Office of Media Affairs MEDICARE FACT SHEET FOR IMMEDIATE RELEASE
More informationOnly in growth, reform, and change, paradoxically enough, is true security to be found.
The Impact of ARRA/HITECH Stimulus, EMR/EHR Initiatives, and Meaningful Use on Laboratories Presented By: Curt Johnson Chief Operating Officer cjohnson@orchardsoft.com Orchard Symposium 2009 - Keynote
More informationMedicare Shared Savings Program Quality Measure Benchmarks for the 2014 Reporting Year
Medicare Shared Savings Program Quality Measure Benchmarks for the 2014 Reporting Year Release Notes/Summary of Changes (February 2015): Issued correction of 2014 benchmarks for ACO-9 and ACO-10 quality
More informationMedicare Physician Group Practice Demonstration
Medicare Physician Group Practice Demonstration Heather Grimsley Medicare Demonstrations Program Group Center for Medicare and Medicaid Innovation Centers for Medicare & Medicaid Services April 2011 PGP
More informationVIII. Dentist Crosswalk
Page 27 VIII. Dentist Crosswalk Overview The final rule on meaningful use requires that an Eligible Professional (EP) report on both clinical quality measures and functional objectives and measures. While
More informationMeaningful Use: Registration, Attestation, Workflow Tips and Tricks
Meaningful Use: Registration, Attestation, Workflow Tips and Tricks Allison L. Weathers, MD Medical Director, Information Services Rush University Medical Center Gregory J. Esper, MD, MBA Vice Chair, Neurology
More informationTABLE OF CONTENTS PREFACE ICD-10 ENHANCEMENTS KEY USABILITY ENHANCEMENTS. MicroMD EMR Update Guide Version 10.0
U P D A T E G U I D E TABLE OF CONTENTS PREFACE Welcome to MicroMD EMR... i How This Guide is Organized... i Understanding Typographical Conventions... i Cross-References... i Text You Type Using the Keyboard...
More informationACO Program: Quality Reporting Requirements. Jennifer Faerberg Mary Wheatley April 28, 2011
ACO Program: Quality Reporting Requirements Jennifer Faerberg Mary Wheatley April 28, 2011 Agenda for Today s Call Overview Quality Reporting Requirements Benchmarks/Thresholds Scoring Model Scoring Methodology
More informationACO Name and Location Allina Health Minneapolis, Minnesota
ACO Name and Location Allina Health Minneapolis, Minnesota ACO Primary Contact Patrick Flesher Director, Payer Contracting & Pioneer ACO Program Email: Patrick.Flesher@allina.com Phone: 612-262-4865 Composition
More informationAllscripts CQS Planning for 2014 Webinar: FAQs
Allscripts CQS Planning for 2014 Webinar: FAQs Listed below are questions asked by attendees based on the CQS Planning for 2014 Webinars, held on May 8, May 28, and May 30, 2014. Answers are provided below.
More informationMeaningful Use Qualification Plan
Meaningful Use Qualification Plan Overview Certified EHR technology used in a meaningful way is one piece of a broader Health Information Technology infrastructure intended to reform the health care system
More informationCash for Clunkers. Meaningful Use: No Cash for Clunkers. EHR Certification & Meaningful Use
Meaningful Use: No Cash for Clunkers EHR Certification & Meaningful Use ANCO/MOASC Business of Oncology: 2010 and Beyond October 28, 2010 Cash for Clunkers 2 1 NO Cash for Clunkers 3 What is a clunker?
More informationADDITIONAL INFORMATION REGARDING EP CLINICAL QUALITY MEASURES FOR 2014 EHR INCENTIVE PROGRAMS
ADDITIONAL INFORMATION REGARDING EP CLINICAL QUALITY MEASURES FOR 2014 EHR INCENTIVE PROGRAMS The table below entitled Clinical Quality s for 2014 CMS EHR Incentive Programs for Eligible Professionals
More informationOBJECTIVES AGING POPULATION AGING POPULATION AGING IMPACT ON MEDICARE AGING POPULATION
OBJECTIVES Kimberly S. Hodge, PhDc, MSN, RN, ACNS-BC, CCRN- K Director, ACO Care Management & Clinical Nurse Specialist Franciscan ACO, Inc. Central Indiana Region Indianapolis, IN By the end of this session
More informationMedicare Shared Savings Program Quality Measure Benchmarks for the 2015 Reporting Year
Medicare Shared Savings Program Quality Measure Benchmarks for the 2015 Reporting Year Release Notes/Summary of Changes (February 2015): Issued correction of 2015 benchmarks for ACO-9 and ACO-10 quality
More informationTuesday, May 6, 2014 12:00 Noon EDT Dial In: 1-877-267-1577 Meeting ID: 997 828 367 No audio available through Webinar
Aligning PQRS with Meaningful Use CQMs in 2014 Tuesday, May 6, 2014 12:00 Noon EDT Dial In: 1-877-267-1577 Meeting ID: 997 828 367 No audio available through Webinar 2 Objectives Discuss benefits of aligning
More informationUnited States Virgin Island Eligible Provider EHR Incentive Program Application Manual
United States Virgin Island Eligible Provider EHR Incentive Program Application Manual Date of Publication: 02.03.2015 Document Version: 1.1 DRAFT Page 1 Privacy Rules The Health Insurance Portability
More informationTotal Health Quality Indicators For Providers 2015
Total Health Quality Indicators For Providers 2015 Adult- Preventive Measure Test/Procedure Parameters Frequency CPT/HCPCS CPT II ICD-9 BMI Assessment BMI Recording 18-74 yrs Yearly G8417, G8418, G8420
More informationElectronic Health Record (EHR) Incentive Program. Stage 2 Final Rule Update Part 2
Office of Medical Assistance Programs Electronic Health Record (EHR) Incentive Program Stage 2 Final Rule Update Part 2 November 7, 2012 Medical Assistance HIT Initiative 1 Office of Medical Assistance
More informationThere have been significant
Managing Clinical Quality Measures for Meaningful Use and PQRS Using the EHR Method These tips will make it easier to qualify. By Seth Flam, DO Charlieaja Dreamstime.com There have been significant changes
More informationMeaningful Use Guidelines: Radiologists
Meaningful Use Meaningful Use (MU) criteria allows providers to demonstrate that they are using certified EHR technology in ways that can be measured significantly in quality and in quantity. Many assume
More informationVermont ACO Shared Savings Program Quality Measures: Recommendations for Year 2 Measures from the VHCIP Quality and Performance Measures Work Group
Vermont ACO Shared Savings Program Quality Measures: Recommendations for Year 2 Measures from the VHCIP Quality and Performance Measures Work Group Presentation to VHCIP Steering Committee August 6, 2014
More informationClinical Quality Measures for Providers
Meaningful Use White Paper Series Paper no. 6a: Clinical Quality Measures for Providers Published September 15, 2010 Clinical Quality Measures for Providers Papers 5a and 5b in this series reviewed the
More informationJanuary 2014 Physician Quality Reporting System (PQRS): What s New for 2014 Purpose Important Changes for 2014 PQRS PQRS Incentive Individual EPs
January 2014 Physician Quality Reporting System (PQRS): What s New for 2014 Purpose This fact sheet includes important information about changes to the Physician Quality Reporting System (PQRS) for 2014.
More informationAETNA BETTER HEALTH OF MISSOURI
Aetna Better Health of Missouri 10 South Broadway, Suite 1200 St. Louis, MO 63102 800-566-6444 AETNA BETTER HEALTH OF MISSOURI HEDIS Quick Reference Billing Guide 2014 Diagnosis and/or procedure codes
More informationMEASURING CARE QUALITY
MEASURING CARE QUALITY Region November 2015 For Clinical Effectiveness of Care Measures of Performance From: Healthcare Effectiveness Data and Information Set (HEDIS ) HEDIS is a set of standardized performance
More informationSUMMARY TABLE OF MEASURE CHANGES
Summary Table of Measure 1 SUMMARY TABLE OF MEASURE CHANGES Guidelines for Physician Measurement Effectiveness of Preventive Care Guidelines for Physician Effectiveness of Care Adult BMI Assessment Weight
More informationMeaningful Use - The Basics
Meaningful Use - The Basics Presented by PaperFree Florida 1 Topics Meaningful Use Stage 1 Meaningful Use Barriers: Observations from the field Help and Questions 2 What is Meaningful Use Meaningful Use
More informationChapter Three Accountable Care Organizations
Chapter Three Accountable Care Organizations One of the most talked-about changes in health care delivery in recent decades is Accountable Care Organizations, or ACOs. Having gained the attention of both
More informationMicroMD EMR version 9.0
MicroMD EMR version 9.0 u p d a t e g u i d e TABLE OF CONTENTS PREFACE Welcome to MicroMD EMR... i How This Guide is Organized... i Understanding Typographical Conventions... i Cross-References... i Text
More informationADDITIONAL INFORMATION REGARDING EP CLINICAL QUALITY MEASURES FOR 2014 EHR INCENTIVE PROGRAMS
ADDITIONAL INFORMATION REGARDING EP CLINICAL QUALITY MEASURES FOR 2014 EHR INCENTIVE PROGRAMS The table below entitled Clinical s for 2014 CMS EHR Incentive Programs for Eligible Professionals contains
More informationVermont ACO Shared Savings Program: Recommendations for Year 2 Quality Measures
Vermont ACO Shared Savings Program: Recommendations for Year 2 Quality Measures Green Mountain Care Board October 9, 2014 10/9/2014 1 ACOs & SSPs Accountable Care Organizations (ACOs) are composed of and
More informationESSENTIA HEALTH AS AN ACO (ACCOUNTABLE CARE ORGANIZATION)
ESSENTIA HEALTH AS AN ACO (ACCOUNTABLE CARE ORGANIZATION) Hello and welcome. Thank you for taking part in this presentation entitled "Essentia Health as an ACO or Accountable Care Organization -- What
More information2016 Physician Quality Reporting System (PQRS) Measure Specification and Measure Flow Guide for Claims and Registry Reporting of Individual Measures
2016 Physician Quality Reporting System (PQRS) Measure Specification and Measure Flow Guide for Claims and Registry Reporting of Individual Measures Utilized by Individual Eligible Professionals for Claims
More informationJames R. Christina, DPM FPMA 2014 Annual Meeting Naples, FL
Stage 2 Meaningful Use: A Deep Dive James R. Christina, DPM FPMA 2014 Annual Meeting Naples, FL Latest CMS Data April 2014 Provider Summary 1 Payment Summary What Stage Am I In? 2 2 CMS Proposed Rule On
More information